Telix Pharmaceuticals has launched a US$550 million convertible bonds offering due 2031 to refinance its existing convertible bonds maturing in 2029. The move represents a proactive capital management decision by the pharmaceutical company, which continues to demonstrate its ability to access debt markets despite operating in the competitive biopharmaceutical sector. The new convertible bonds will be listed on Singapore Exchange Securities Trading Limited and will be convertible into fully paid ordinary shares in Telix at an initial conversion price set at a premium to the company’s current share price.
The refinancing addresses near-term maturity obligations while extending Telix’s debt runway by approximately two years. By securing US$550 million in new convertible bonds, Telix intends to use the net proceeds to repurchase the existing convertible bonds due 2029, with any surplus funds directed toward general corporate purposes. This structure provides the company with additional flexibility in managing its capital structure and reduces the risk of a sudden maturity cliff in 2029. The convertible nature of the bonds means the financing remains non-dilutive to existing shareholders until any potential future conversions occur, making it an attractive option for a company focused on preserving shareholder value during its commercialization phase.
The offering incorporates several notable features designed to appeal to institutional investors. A concurrent delta placement of ordinary shares will occur to facilitate hedging activity by convertible bond investors, with the clearing price from this placement serving as the reference share price for calculating conversion terms. Additionally, the Stock Lender, identified as Elk River Holdings Pty Ltd acting as trustee for The Behrenbruch Family Trust (in which Managing Director Christian Behrenbruch holds an indirect interest), will enter into a stock lending facility with an affiliate of J.P. Morgan to support the offering mechanics. These arrangements are standard market practice for convertible offerings but highlight the structured approach being taken to execute the refinancing.
The concurrent reverse bookbuilding process for repurchasing existing convertible bonds adds another layer of optionality to the transaction. Rather than repurchasing a fixed amount, Telix will determine both the number of bonds repurchased and the purchase price based on indications of interest from existing bondholders. This approach could result in either a full refinancing of existing obligations or a partial repurchase with the remaining bonds allowed to mature, depending on market conditions and bondholder participation.
For investors, this refinancing demonstrates Telix’s access to capital markets and its commitment to managing debt obligations prudently. The ability to refinance at favorable terms reflects ongoing investor confidence in the company’s pipeline and commercial prospects. However, the announcement also signals that Telix remains reliant on debt financing rather than achieving cash generation from operations, which remains an important metric to monitor as the company advances its marketed products and late-stage clinical programs. The final terms will be determined through the bookbuild process expected to conclude prior to market open on April 15, 2026. This announcement has been flagged as price sensitive and material to the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
